Sun Pharm Inds Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUN PHARM INDS, and when can generic versions of SUN PHARM INDS drugs launch?
SUN PHARM INDS has two hundred and twenty-eight approved drugs.
There are eleven US patents protecting SUN PHARM INDS drugs. There are eleven tentative approvals on SUN PHARM INDS drugs.
There are thirty-seven patent family members on SUN PHARM INDS drugs in thirteen countries and two hundred and nineteen supplementary protection certificates in sixteen countries.
Summary for Sun Pharm Inds
| International Patents: | 37 |
| US Patents: | 11 |
| Tradenames: | 170 |
| Ingredients: | 161 |
| NDAs: | 228 |
Drugs and US Patents for Sun Pharm Inds
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds | OCTREOTIDE ACETATE | octreotide acetate | INJECTABLE;INJECTION | 077330-001 | Mar 4, 2008 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Sun Pharm Inds Inc | LEVORPHANOL TARTRATE | levorphanol tartrate | TABLET;ORAL | 213906-001 | Jun 17, 2021 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-004 | May 25, 2012 | AB2 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ||||
| Sun Pharm Inds Ltd | CEPHALEXIN | cephalexin | FOR SUSPENSION;ORAL | 065081-001 | Jul 27, 2001 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Sun Pharm Inds Ltd | QUINAPRIL HYDROCHLORIDE | quinapril hydrochloride | TABLET;ORAL | 090800-001 | Jun 18, 2009 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Sun Pharm Inds Ltd | GLYCOPYRROLATE | glycopyrrolate | TABLET;ORAL | 040844-001 | Aug 18, 2009 | AA | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Sun Pharm Inds | OLANZAPINE | olanzapine | TABLET, ORALLY DISINTEGRATING;ORAL | 090881-003 | Feb 28, 2012 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sun Pharm Inds
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-006 | Aug 15, 2014 | 9,078,925 | ⤷ Subscribe |
| Sun Pharm Inds Inc | LEVULAN | aminolevulinic acid hydrochloride | SOLUTION;TOPICAL | 020965-001 | Dec 3, 1999 | 8,758,418 | ⤷ Subscribe |
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-002 | May 25, 2012 | 9,089,534 | ⤷ Subscribe |
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-003 | May 25, 2012 | 8,367,102 | ⤷ Subscribe |
| Sun Pharm Inds Inc | BACTRIM | sulfamethoxazole; trimethoprim | INJECTABLE;INJECTION | 018374-001 | Approved Prior to Jan 1, 1982 | RE28636 | ⤷ Subscribe |
| Sun Pharm Inds Inc | LEVULAN | aminolevulinic acid hydrochloride | SOLUTION;TOPICAL | 020965-001 | Dec 3, 1999 | 5,211,938 | ⤷ Subscribe |
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-006 | Aug 15, 2014 | 8,367,102 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SUN PHARM INDS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 30 mg and 40 mg | ➤ Subscribe | 2012-12-31 |
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2013-06-19 |
| ➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2016-05-16 |
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2013-01-07 |
| ➤ Subscribe | Capsules | 35 mg | ➤ Subscribe | 2015-11-25 |
International Patents for Sun Pharm Inds Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2020267186 | ⤷ Subscribe |
| Australia | 2023201112 | ⤷ Subscribe |
| Mexico | 2021014175 | ⤷ Subscribe |
| Australia | 2022209242 | ⤷ Subscribe |
| South Korea | 20190003711 | ⤷ Subscribe |
| Lithuania | 3452039 | ⤷ Subscribe |
| European Patent Office | 3452039 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sun Pharm Inds Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0247633 | 62/1997 | Austria | ⤷ Subscribe | PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107 |
| 0720599 | 26/2005 | Austria | ⤷ Subscribe | PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON KOMBINIERT MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 1-25673 - 1-25676 20041228; FIRST REGISTRATION: DE 58874.00.00 - 58874.03.00; 58878.00.00 - 20040402 |
| 0236940 | 97C0053 | Belgium | ⤷ Subscribe | PRODUCT NAME: LETROZOLE; NAT. REGISTRATION NO/DATE: 206 IS 241 F 3 19970616; FIRST REGISTRATION: FR 341 474.2 1996072 |
| 1110543 | SPC/GB08/005 | United Kingdom | ⤷ Subscribe | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
| 0296749 | 09C0055 | France | ⤷ Subscribe | PRODUCT NAME: ANASTROZOLE, EVENTUELLEMENT SOUS LA FORME D’UN SEL D’ADDITION ACCEPTABLE EN MEDECINE PHARMACEUTIQUE; REGISTRATION NO/DATE IN FRANCE: NL 21126 DU 19961227; REGISTRATION NO/DATE AT EEC: 12619/0106 DU 19950811 |
| 0502314 | SPC/GB02/037 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
| 1602370 | 09C0020 | France | ⤷ Subscribe | PRODUCT NAME: COMBINAISON COMRENANT L’ALISKIREN SOUS FORME DE BAE LIBRE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, ET L’HYDROCHLOROTHIAZIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/08/491/001 DU 20090116; REGISTRATION NO/DATE AT EEC: 58935 01-04 DU 20081028 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
